Navigation Links
Aoxing Pharmaceutical Company Has No Comment on Unusual Trading Activity
Date:6/23/2011

JERSEY CITY, N.J., June 23, 2011 /PRNewswire/ -- Aoxing Pharmaceutical (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, reported that in light of the unusual market activity in the Company's common stock today, June 23, the NYSE staff has contacted the Company in accordance with its usual practice. In response, the Company stated that its policy is not to comment on unusual market activity or rumors.

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the Chinese State Food and Drug Administration (SFDA). It has joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. It also has strategic alliance partnerships with QRxPharma, Phoenix PharmaLabs, Inc. and American Oriental Bioengineering, Inc. For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and the Company's actual results may differ materially due to a number of factors, many of which are beyond its ability to predict or control, including, among many others, the Company's ability to commercialize on the patent subject of this press release, its ability to develop new therapeutic delivery methods, to complete GMP certification of the workshops, obtain process approvals, develop the product line as and when anticipated. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by the Company. The Company operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. These forward-looking statements are based on the Company's current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those anticipated by the Company. The Company undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

CONTACT:  

Aoxing Pharmaceutical Company:
Bob Ai
Chief Financial Officer
646-367-1767
investor.relations@aoxingpharma.com

Investor Relations:
The Trout Group
Brian Korb
646-378-2923
bkorb@troutgroup.com


'/>"/>
SOURCE Aoxing Pharmaceutical Company, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
2. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
3. Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... DIEGO , Feb. 11, 2016 ... groundbreaking cell-isolation method that opens the door to ... until now have been impossible to isolate with ... to isolate specific tumor types in various stages ... genetic variants of these cells that are clinically ...
(Date:2/11/2016)... Conn. , Feb. 11, 2016  NanoViricides, ... that it has entered into an agreement with ... its nanoviricides® drug candidates in standard animal models ... Romanowski , Research Director. Dr. Romanowski has extensive ... discovery. --> Eric Romanowski , ...
(Date:2/11/2016)... -- North America , Europe ... global market is expected to reach USD 20,190.1 Million by 2020 ... 10.2%. --> North America , ... The global market is expected to reach USD 20,190.1 Million by ... of 10.2%. --> According to a new market research ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that ... Bank of Eastern Michigan last Friday in order to aid in the Flint water ... to include a facility located in Clio, only 15 miles away from Flint. , ...
(Date:2/10/2016)... California (PRWEB) , ... February 10, 2016 , ... ... are working together to expand dental health services to the developmentally disabled in ... We Care Dental’s operations to a new facility at 71-949 Highway 111, Suite ...
(Date:2/10/2016)... Middletown, PA (PRWEB) , ... February 10, 2016 , ... ... to offer two webinars in February 2016. Each webinar features a dynamic expert ... therapy to benefit their athletes, patients and facilities. Both events are free to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced ... Emergency Medicine , an emergency medicine professional association, to support the organization's newly ... The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency physicians ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... of a master charity program created to assist the local community. Pledging to ... community leaders and nonprofit organizations in the area. Their goal is to bring ...
Breaking Medicine News(10 mins):